VR Logo

Humacyte Inc. (HUMA) download report


Healthcare | Biotechnology & Pharma Research

Humacyte Inc. (HUMA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

IPO Date: 26-Aug-2021

Founder, Pres, CEO & Director: Dr. Laura E. Niklason M.D., Ph.D.

CFO, Chief Corp. Devel. Officer & Treasurer: Mr. Dale A. Sander

Listing: NASDAQ: HUMA

Country: United States

Headquarters: Durham, NC

Website: https://www.humacyte.com

Key Facts

Market cap: $346.10 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-36.87 Mln

Cash: $206.22 Mln

Total Debt: $23.34 Mln

Insider's Holding: 49.77%

Liquidity: Low

52 Week range: $3.07 - 17.45

Shares outstanding: 103,005,000

Stock Performance

Time Period Humacyte (HUMA) S&P BSE Sensex S&P Small-Cap 600
YTD-55.45-8.99-19.23
1 month-41.27-3.40-9.35
3 months-52.01-8.50-16.59
1 Year--0.89-17.36
3 Years--10.415.90
5 Years--11.435.77
10 Years--11.779.78
As on 30-Jun-2022